Beside cytotoxic drugs, other drugs can impact men's fertility through various mechanisms. Via the modification of the hypothalamic-pituitary-gonadal axis hormones or by non-hormonal mechanisms, drugs may directly and indirectly induce sexual dysfunction and spermatogenesis impairment and alteration of epididymal maturation. This systematic literature review summarizes existing data about the negative impact and associations of pharmacological treatments on male fertility (excluding cytotoxic drugs), with a view to making these data more readily available for medical staff. In most cases, these effects on spermatogenesis/sperm maturation/sexual function are reversible after the discontinuation of the drug. When a reprotoxic treatment cannot be stopped and/or when the impact on semen parameters/sperm DNA is potentially irreversible (Sulfasalazine Azathioprine, Mycophenolate mofetil and Methotrexate), the cryopreservation of spermatozoa before treatment must be proposed. Deleterious impacts on fertility of drugs with very good or good level of evidence (Testosterone, Sulfasalazine, Anabolic steroids, Cyproterone acetate, Opioids, Tramadol, GhRH analogues and Sartan) are developed.
INTRODUCTION
Among the aetiological factors involved in male infertility, drug-related illnesses must be investigated (Jarow et al., 2010) . If a patient is taking a drug, the time when the treatment was started, its duration and the period during which it was taken (was it a critical period during testicular maturation?) and the dose are important factors to note (Jungwirth et al., 2015) . This information can be very useful in the event of an alteration of spermatogenesis or erectile or ejaculatory function.
However, up to now very little work has been performed to summarize the impact of drugs on male fertility with the exception of cancer treatments (Lee et al., 2006; Lambertini et al., 2016) . It is important and demanded to establish levels of scientific proof for each molecule in question, to be able to determine the actual impact of the treatment among the other risk factors often associated in the same infertile patient.
This research aims to gather together the available data on the negative impact of pharmacological treatments on male fertility: the impacts on spermatogenesis and semen parameters, as well as impacts on sexual function are studied. This research also includes the recommendations for treating fertility and sexual function issues in men who take the various treatments studied. Medications with an effect on semen and/or sexual function proved with a good level of evidence are developed. The study does not involve the impacts of cytotoxic agents, that is, microtubule disrupting agents and DNA modifying agents, generally used for the treatment of cancer.
MATERIALS AND METHODS
This systematic literature review was performed by drawing on three biomedical literature and academic electronic databases: PubMed/MEDLINE, ScienceDirect and Google Scholar. This research collates data that is related to the effects of drug treatments (excluding cytotoxic molecules) on male fertility. These treatments were divided into subgroups depending on whether the incriminated molecule caused spermatogenesis/post-testicular maturation disorders (direct or indirect effect) or sexual function disorders. For each subgroup the data search was performed using the following respective key words:
Impact of drugs on spermatogenesis and sperm parameters: "Medical therapy, drugs. . . and. . . effects on spermatogenesis, toxicity on spermatogenesis, gonadal impact, sperm parameters, male infertility, fertility on men" to begin with, then more specific terms were used after the initial data had been gathered: "Immunosuppressive therapy dermatological medication, Sulphasalazine, opiates, antidepressants, antihypertensive drugs, Tamsulosine, antiepileptics, antiretrovirals therapy, antibiotics, Ketoconazole, anabolic steroids, testosterone, Finasteride, Colcicine, Cimetidine. . . and. . . effects on spermatogenesis, toxicity on spermatogenesis, gonadal impact, sperm parameters, male infertility, fertility on men".
Impact of drugs on sexual function: "Medical therapy, drugs. . . and. . . erectile dysfunction/disorders, impotence, ejaculation disorders, retrograde ejaculation, anejaculation, sexual dysfunction, testosterone level, male infertility, fertility on men" to begin with, then more specific terms were used after the initial data have been gathered: "corticosteroid, antidepressants, antipsychotic drugs, benzodiazepines antihypertensive drugs, diuretics, alphablockers, Cyproterone acetate, Finasteride, antiepileptics, opiates, statins, fibrates . . . and. . . erectile dysfunction/disorders, impotence, ejaculation disorders, retrograde ejaculation, anejaculation, sexual dysfunction, testosterone level, male infertility, fertility on men".
Abstracts and citations identified via the three databases were reviewed and evaluated for relevance to the question. References cited in the reviewed articles were analysed for additional primary articles not identified in the first search. The search was limited to articles written in English language or in French language and published until May 01, 2016. The studies that were selected concerned men; studies on animal models were used in a handful of cases in which few studies on men were available.
We also drew on the recommendations of learned societies (American Society of Clinical Oncology, European Society of Human Reproduction and Embryology, American Society of Transplantation, European Society for Organ Transplantation, Society of Urology, Soci et e Franc ßaise d'Urologie, Society of Toxicology, European Federation of Endocrine Societies and International Society for Sexual Medicine), data from the Centre de R ef erence sur les Agents T eratog enes (CRAT) and the work of reference containing all the summaries of product characteristics of drugs used in France (VIDAL Hoptimal 2016) .
Levels of scientific evidence were established for each drug from the type of studies available and the methodology that was used. To define these levels of evidence, we drew on data from Sackett and the Centre Cochrane Franc ßais (Sackett, 2000 ; D efinir le meilleur type d' etude | Centre Cochrane Franc ßais 2016). Metaanalyses and randomized controlled trials with a high statistical power thus constituted a high level of scientific evidence. Randomized controlled trials with a low statistical power, prospective comparative studies and cohort studies provided a fairly good level of evidence. Case-control studies and retrospective studies constituted a low level of evidence. Lastly, case series and studies in animals constituted a very low level of evidence. Studies with a satisfactory level of evidence must also have had little bias, a high statistical power and a statistical analysis that was suited to the study objectives. In the case of literature reviews, we referred to the scientific papers that were selected in the review to obtain a level of evidence that would be as reliable as possible (Fig. 1) .
RESULTS
A drug treatment can affect spermatogenesis by interfering with the exocrine function of the testes by altering the germ cells and/or the Sertoli cells. Sertoli cells play a support role in the survival and differentiation of germ cells. When a drug interferes with the endocrine function of the testes by altering Leydig cells or disrupts the hormone regulation system (at the level of the hypothalamic-pituitary axis), the resulting drop in testosterone can also impact spermatozoa production (Fig. 2) . Lastly, any molecule that is likely to modify intratesticular vascularization or alter epididymal function can affect sperm parameters (Creasy, 2001) (Fig. 2) .
The drug treatments that are responsible for spermatogenesis disorders or sperm parameter alterations, and the recommendations for treating infertile men, are given in Table 1 .
The mechanisms of action (when they are described) through which a pharmaceutical molecule can affect sperm parameters are described in the sections below.
The effects of pharmaceutical molecules (excluding cytotoxic agents) on spermatogenesis and sperm parameters are generally reversible when the treatment is discontinued (provided that the medication is the sole causal factor). If it is impossible to stop a therapy, the use of antioxidant supplements is sometimes proposed.
Symptomatic treatment of sperm parameter alteration with antioxidants
Oxidative stress (resulting from an imbalance between reactive oxygen species (ROS) production and antioxidant system activity) is thought to be involved in the pathophysiology of male infertility. It is responsible, among other things, for a loss of membrane and DNA integrity in the spermatozoa, thus altering their ability to fertilize the oocyte. A number of studies suggest that supplementation with oral antioxidants (vitamins C and E, zinc, selenium, folates, carnitine and carotenoids) could improve the sperm quality in infertile patients whose semen is found to contain excessive ROS (evidenced by reduced DNA fragmentation, increased sperm motility, etc.). However, the evidence that confirms a beneficial effect from these molecules is far from convincing, as other data do not indicate any improvement with this type of treatment (Ross et al., 2010) .
Studies that have evaluated a possible association between a drug treatment and elevated ROS in semen are almost non-existent. In animals, the administration of cytotoxic molecules (Cyclophosphamide) can reduce catalase (a component of the antioxidant enzyme system) activity in the testes, resulting in oxidative stress (Tremellen, 2008) . Other drugs, such as Sulfasalazine, acetylsalicylic acid and antibiotics, could also stimulate ROS production (Narayana, 2008a; Tremellen, 2008; Alonso et al., 2009) .
Antioxidants are thought to be ineffective in men whose hypofertility is not caused by oxidative stress. Any alteration in the optimal balance between the concentration of antioxidant molecules and that of ROS could even prove to be harmful because the physiological production of ROS plays an important role in the spermatozoa capacitation and/or acrosome reaction process and in oocyte fertilization capability (Bolle et al., 2002; M en ezo et al., 2007; Desai et al., 2009 ). Therefore, antioxidants should not be systematically prescribed in cases of sperm parameter alteration.
Mechanisms of drugs action on sexual functions and recommendations
An erection results from the swelling of the corpora cavernosa, which becomes engorged with blood after a series of neurological events and the activation of vascular mediators that are involved in the physiology of erectile function (Droupy, 2005; Gratzke et al., 2010) (Fig. 4) . When a bioactive molecule interferes with these mechanisms, erectile dysfunction can result. Nocturnal erections are androgen dependent (erections resulting from sexual stimulation are much less so). Therefore, an androgen deficiency can be a cause of erectile disorders (Courtois & Bonierbale, 2016) .
Ejaculation occurs in response to a series of neuromuscular events that lead to the emission and then the expulsion of semen from the urethra. Any alteration in these events can modify ejaculatory function and can be a cause of ejaculatory disorders (total or partial retrograde ejaculation into the bladder, anejaculation, delayed ejaculation, etc.) (Rigot et al., 2013) .
Male sexual activity is dependent on the dopaminergic system and the sex hormones (androgens). Its cerebral control is subject to the inhibitory influence of the opioid system. A dopamine or androgen deficiency can thus cause a loss of sexual desire (Courtois & Bonierbale, 2016) . Similarly, if a pharmaceutical substance affects the central nervous system, it can also have an adverse effect on male libido (Rigot et al., 2013) .
The drug treatments that are responsible for an alteration in sexual function are presented in Table 2 .
The mechanisms of action (when they have been described) through which a pharmaceutical molecule can affect sexual function are described in the sections below.
The treatment of erectile and ejaculatory dysfunction is based initially on psychosexual therapy for the couple. When sexual disorders arise during drug treatments, the discontinuation of treatment with the incriminated molecule generally restores the reproductive function of men who wish to have children. When it is impossible to stop a therapy, symptomatic treatment of the disorders can be considered.
Symptomatic treatments for erectile disorders
Type 5 phosphodiesterase inhibitors (Sildenafil, Tadalafil and vardenafil) facilitate muscular relaxation in the corpus cavernosum that brings about an erection, the principal mediator of which is nitric oxide. These medications must be prescribed in strict accordance with their adverse effects and precautions for use (beware of nitro-derivatives, NO liberators, Ritonavir, alpha-blockers, cardiovascular conditions, etc.) (Cuzin et al., 2011; VIDAL Hoptimal 2016) . The efficacy of Yohimbine (an a2-adrenergic receptor antagonist) has not been demonstrated. The injection of PGE1 (Alprostadil) into the corpus cavernosum is a second-line treatment for erectile disorders. As the molecule passes into the semen, these treatments must not be used in men who wish to conceive. As a last resort, the use of a vacuum device (a mechanical system that brings about a passive erection) or penile implants may be proposed (Cuzin et al., 2011) . 642 Andrology, 2017, 5, 640-663 Symptomatic treatments for ejaculatory disorders The treatment of ejaculatory disorders that are induced by a pharmacological treatment becomes a complex matter when the discontinuation of the drug proves to be impossible. Before instigating this type of treatment in men of reproductive age, semen cryopreservation should be considered. In the case of retrograde ejaculation, the collection of alkalinized urine followed by a search for spermatozoa and cryopreservation can be proposed with a view towards the pursuit of assisted reproduction techniques. In the case of total anejaculation or if the quantity of spermatozoa that was collected in the urine is insufficient for freezing, spermatozoa (epididymal or testicular) can be retrieved surgically. The pharmacological treatments and penile vibratory stimulation techniques that are used to treat anejaculation in Table 1 Impact of drugs on spermatogenesis and sperm parameters (Nudell et al., 2002; Schlosser et al., 2007; Brezina et al., 2012) Pharmacological class Family and molecules (references) Impact on spermatogenesis and sperm parameters Guidelines
Immunosuppressive drugs mTOR inhibitors: Sirolimus (Bererhi et al., 2003; Huyghe et al., 2007; Zuber et al., 2008; Roa et al., 2009; Rovira et al., 2012; Chen et al., 2013; He et al., 2013; Leroy et al., 2015 ; VIDAL Hoptimal 2016) Calcineurin inhibitors: Ciclosporine, Tacrolimus (Haberman et al., 1991; Iwasaki et al., 1995; Østensen et al., 2006; Grunewald et al., 2007; Chen et al., 2013; He et al., 2013; Millsop et al., 2013; Palomba et al., 2014; Grunewald & Jank, 2015; Leroy et al., 2015 ; CRAT -Centre de r ef erence sur les agents t eratog enes chez la femme enceinte 2016; VIDAL Hoptimal 2016) Antimetabolites: Mycophenolate mofetil, Azathioprine (Dejaco et al., 2001; Østensen, 2004; Ligumsky et al., 2005; Østensen et al., 2006; Grunewald et al., 2007; Hoeltzenbein et al., 2012; Jones et al., 2013; Millsop et al., 2013; Palomba et al., 2014; Leroy et al., 2015;  CRAT -Centre de r ef erence sur les agents t eratog enes chez la femme enceinte 2016; VIDAL Hoptimal 2016) Other: Fingolimod (Karlsson et al., 2014; Leroy et al., 2015) Sirolimus: Reversible alteration of sperm parameters; Decreased count, motility and morphology of spermatozoa Decreased testosterone level Relatively Good Level of Evidence Ciclosporine: Rat: Decreased count and motility of spermatozoa Inhibition of testosterone synthesis Very Low Level of Evidence Human being: Impact on spermatogenesis cannot be excluded A priori, no effect on male fertility (lack of data) Low Level of Evidence Tacrolimus (Martini et al., 2003) Sulfasalazine (Birnie et al., 1981; Toovey et al., 1981; O'Mor ain et al., 1984; Ragni et al., 1984; Steeno, 1984; Kjaergaard et al., 1989; Niederberger, 2002; Østensen, 2004; Østensen et al., 2006; Grunewald et al., 2007; Alonso et al., 2009; Palomba et al., 2014; Leroy et al., 2015; VIDAL Hoptimal 2016 (Estrada et al., 1997; Mahadevan et al., 2005; Østensen et al., 2006; Millsop et al., 2013; Micu et al., 2014; Palomba et al., 2014; Ramonda et al., 2014; Grunewald & Jank, 2015; Leroy et al., 2015 ; CRAT -Centre de r ef erence sur les agents t eratog enes chez la femme enceinte 2016; VIDAL Hoptimal 2016) (Yilmaz et al., 1999; Cicero et al., 2002) Cocaine (Bracken et al., 1990; George et al., 1996) General reviews: (Pake et al., 1994a; Daniell, 2002 , 1977; Wong & Lee, 1982; Millsop et al., 2013) (Schlegel et al., 1991; Hargreaves et al., 1998) Aminosides: Gentamicine, Neomycine, Streptomycine (Schlegel et al., 1991; Narayana, 2008b; Khaki, 2008 (Haidl et al., 2008; Y aniz et al., 2010; Hamada et al., 2011; Boitrelle et al., 2012) Reversible effect after discontinuation Antibiotic therapy recommended for testicular infections and epididymitis (Haidl et al., 2008; Y aniz et al., 2010; Hamada et al., 2011; Boitrelle et al., 2012) Antimalarials Chloroquine (Okanlawon et al., 1993; Adeeko & Dada, 1994; Hargreaves et al., 1998; Østensen, 2004; Østensen et al., 2006; Grunewald et al., 2007; Millsop et al., 2013; Leroy et al., 2015) Rat (Tanrikut & Schlegel, 2007) , Buspirone (Tanrikut & Schlegel, 2007) and Lithium salts (Toghyani et al., 2013) patients with spinal cord injuries do not appear to be indicated in this context (Colpi et al., 2004) .
Immunosuppressants Sirolimus, which is used to prevent organ transplant rejection, causes seminiferous tubule dystrophy with a reversible alteration of the sperm parameters characterized by decreased count, motility and morphology of spermatozoa (Bererhi et al., 2003; Huyghe et al., 2007; Zuber et al., 2008; Chen et al., 2013; He et al., 2013; Leroy et al., 2015; VIDAL Hoptimal 2016) . Indeed, Sirolimus blocks spermatogenesis at the level of the spermatogonia, gradually lowering the number of spermatocytes, spermatids and spermatozoa (Rovira et al., 2012) . Sirolimus also reduces StAR protein expression, which plays a role in the transport of cholesterol, a precursor for testosterone synthesis in the Leydig cells. This lowers the level of intratesticular testosterone, on which spermatogenesis depends to function correctly. Sirolimus may also inhibit the kiss system (and hence pulsatile GnRH secretion) at the hypothalamic level (Roa et al., 2009 ).
Anti-inflammatories and salicylates
Sulfasalazine at chronic dose causes a reversible alteration of sperm parameters. Indeed, a chronic dose taken for more than 2 months results in a decreased sperm count, motility and morphology (Toovey et al., 1981; O'Mor ain et al., 1984; Leroy et al., 2015) . In the study of O'Mor ain et al., Sulfasalazine was associated with oligoasthenospermia in over 60% of treated men with inflammatory bowel disease. However, sperm counts in patients receiving discontinued Sulfasalazine treatment for more than 3 months were not significantly different than in patients without treatment (O'Mor ain et al., 1984) .
The precise alteration mechanism remains unexplained. The mechanism may consist of a direct toxic effect of the molecule on immature spermatozoa. The active metabolite of Sulfasalazine, Sulphapyridine, may cause oxidative stress, with a knock-on effect on sperm quality (Alonso et al., 2009 ). Sulfasalazine may also affect the serum testosterone level as a result of an inhibitory effect at the level of the hypothalamic-pituitarygonadal axis, although this theory is controversial. The harm to sperm parameters can be reversed 2-3 months after stopping the treatment (Birnie et al., 1981; Toovey et al., 1981; O'Mor ain et al., 1984; Ragni et al., 1984; Steeno, 1984; Kjaergaard et al., 1989; Niederberger, 2002; Nudell et al., 2002; Østensen et al., 2006; Grunewald et al., 2007; Schlosser et al., 2007; Palomba et al., 2014; VIDAL Hoptimal 2016) .
Acetylsalicylic acid and, more rarely, non-steroidal antiinflammatories (administered chronically) can affect sperm quality by decreasing sperm count, motility, vitality and morphology. The effects are reversible and dose related (Mendonc ßa et al., 2000; Martini et al., 2003) . They reversibly or irreversibly inhibit the cyclo-oxygenase enzymes that are responsible for prostaglandin synthesis. However, prostaglandins may be involved in the control of spermatogenesis and testicular steroidogenesis and in the acrosome reaction of spermatozoa (Joyce et al., 1987) .
Opiates
Opiates stimulate prolactin secretion by inhibiting the tuberoinfundibular dopaminergic activity of hypothalamus (Fig. 3) ; it inhibits the hypothalamic-pituitary axis and causes hypogonadotropic hypogonadism. This may lower the intratesticular testosterone level, however, the gametic effects remain difficult to evaluate (Bracken et al., 1990; Pake et al., 1994a;  George et al., 1996; Yilmaz et al., 1999; Freeman et al., 2000; Cicero et al., 2002; Daniell, 2002; Schlosser et al., 2007; Katz & Mazer, 2009) . Chronic use of cocaine affects sperm quality by decreasing sperm count, motility, vitality and morphology (Bracken et al., 1990) . According to the literature review of Katz & Mazer (2009), long-term opioid therapy induces hypogonadism owing to central suppression of hypothalamic secretion of gonadotropin-releasing hormone (Fig. 2) . As a matter of facts, opioids cause infertility, loss of libido and impotence in men (Pake et al., 1994a; Yilmaz et al., 1999; Daniell, 2002; Schlosser et al., 2007; Katz & Mazer, 2009; Gratzke et al., 2010) .
Antiandrogens
Finasteride, which is used to treat benign prostatic hyperplasia, is a specific inhibitor of 5a-reductase. This intracellular enzyme converts testosterone into dihydrotestosterone, which has a stronger affinity than testosterone for the androgen receptors in the target cells. A drop in dihydrotestosterone expression can have adverse effects on sperm parameters and male reproductive function. Amory et al. conducted a randomized, doubleblinded, placebo-controlled trial in 99 healthy men randomly assigned to receive dutasteride, finasteride or placebo once daily for 1 year. They concluded that 5 alpha-reductase inhibitors significantly decrease sperm count and mobility (but not morphology) with reversible effects 3-4 months after stopping the treatment (Amory et al., 2007) . Men are advised to stop taking Finasteride before conceiving (Millsop et al., 2013; Samplaski et al., 2013; VIDAL Hoptimal 2016) .
Erectile and, more rarely, ejaculatory disorders can also arise during treatment. The precise mechanism of the sexual dysfunction has not been clearly established (Carbone & Hodges, 2003; Wessells et al., 2003; Giuliano, 2006; Mondaini et al., 2007; Giuliano & Droupy, 2013; VIDAL Hoptimal 2016) .
Cyproterone acetate is a palliative treatment for prostate cancer. This powerful antiandrogen competitively inhibits the binding of 5-a-dihydrotestosterone to its cystolic receptor in the target cells. At a central level, cyproterone acetate has an antigonadotropic effect, which reduces testosterone synthesis by the testes (Meriggiola et al., 1997; Schlosser et al., 2007; VIDAL Hoptimal 2016) . A prospective study of 25 volunteer men treated or not with cyproterone acetate during 16 weeks showed a decrease in sperm concentration, motility and morphology. For one patient, azoospermia was described (Wang & Yeung, 1980) . The molecule's effect on sperm parameters is reversible within 6-22 weeks of stopping the treatment (Meriggiola et al., 1997; Schlosser et al., 2007; VIDAL Hoptimal 2016) .
Cyproterone acetate and non-steroidal antiandrogens are used in the treatment of prostate cancer. By preventing androgens from acting on their targets, these medications also cause a loss of erectile function and libido. In a prospective study of 310 patients with metastatic prostate cancer, the sexual function was evaluated before and after the introduction of antiandrogens treatments. Under cyproterone acetate treatment, spontaneous erections and sexual activity has declined but the loss was slow. However, the initial rate of sexual dysfunction was probably higher than in the age-matched general population (Schr€ oder et al., 2000) . Non-steroidal antiandrogens do not have any antigonadotropic effects, indeed these medications are targeted to the prostate. Consequently, their sexual tolerance profile appears to be better than the other antiandrogens, particularly Bicalutamide (Schr€ oder et al., 2000; Iversen et al., 2001; Droupy, 2005; Schlosser et al., 2007; Gratzke et al., 2010; Giuliano & Droupy, 2013; VIDAL Hoptimal 2016) .
Alpha-blockers
Alpha-blockers are antagonists of the a 1 -adrenergic receptors of smooth muscle cells, including those of the urinary tract. They are used to treat high blood pressure and benign prostatic hyperplasia. Some alpha-blockers, such as Tamsulosin, also have an affinity for dopamine and serotonin receptors at the central level. The interaction between Tamsulosin and certain central neurotransmitters could contribute to the observed effects on sperm parameters but the mechanism of the alteration remains unknown (Hellstrom & Sikka, 2009; Brezina et al., 2012) . Use of Tamsulosin results in reversible semen alteration characterized by decreased ejaculate volume, sperm count, motility and morphology . The chemical structure of Afluzosin, a quinazoline derivative, is very different from that of Tamsulosin, which is a sulphonamide derivative. These structural differences could explain why the harmful effects of Tamsulosin on sperm parameters do not occur with Afluzosin use (Hellstrom & Sikka, 2009 ).
Tamsulosin and Silodosin frequently cause ejaculatory disorders, such as retrograde ejaculation or anejaculation. Retrograde ejaculation can occur as a result of reduced smooth muscle tone at the neck of the bladder. Anejaculation is thought to be caused by the defective emission or the defective contraction of the bulbospongiosus muscles; indeed, the thoracic and lumbar adrenergic sympathetic nervous system is responsible for the contraction of the smooth muscle fibres of the seminal tract and the bladder neck. Most of the time, orgasms are maintained. If ejaculatory disorders arise, the use of a different alpha-blocker may be recommended (Hendry, 1998; Nudell et al., 2002; Carbone & Hodges, 2003; Giuliano, 2006; Hellstrom & Sikka, 2006; Shimizu et al., 2010; Roehrborn et al., 2011; Brezina et al., 2012; Giuliano & Droupy, 2013; VIDAL Hoptimal 2016) . Alpha-blockers do not cause erectile dysfunction (Droupy, 2005; Giuliano, 2006) .
Anabolic steroids and testosterone
Hormone-based treatments and testosterone inhibit the hypothalamic-pituitary-gonadal axis and lead to hypogonadotropic hypogonadism (Fig. 2) . This results in the partial or complete inhibition of spermatogenesis, leading to oligospermia, cryptozoospermia or even azoospermia. (R€ onnberg, 1980 
Diuretics
Spironolactone has a peripheral antiandrogen effect by inhibiting the adrenal and testicular cytochromes P450 that are involved in testosterone biosynthesis. In addition, it is thought to prevent androgens from binding to the target cells through a competition phenomenon at the receptor level (Caminos-Torres et al., 1977; Wong & Lee, 1982; Millsop et al., 2013) . These antiandrogen properties can cause erectile dysfunction and decreased desire (Clark, 1965; Caminos-Torres et al., 1977; Schlosser et al., 2007; Gratzke et al., 2010; VIDAL Hoptimal 2016) . Moreover, impairment of sperm motility can be observed (Caminos-Torres et al., 1977; Millsop et al., 2013) .
The effect of thiazide diuretics on sexual function is more controversial as a result of the presence of confounding factors: reduced vascular resistance, volume depletion and electrolytic changes. Erectile dysfunction appears relatively soon after the initiation of treatment but remains tolerable most of the time. In hypertensive subjects, the discontinuation of treatment is not recommended. However, in young men, it is preferable to use a different class of antihypertensives such as sartans, in order to limit the occurrence of these disorders (Grimm et al., 1997; Hendry, 1998 
Anti-infective agents
Most antibiotics alter sperm motility in vitro, but in vivo data are almost non-existent.
Nitrofurantoin is described as being potentially harmful for spermatogenesis through a direct gonadotoxic effect at the level of primary spermatocytes and spermatids (a lower nucleic acid level in the affected germ cells) (Nelson & Bunge, 1957; Yunda & Kushniruk, 1974; VIDAL Hoptimal 2016) . At high dose, nitrofurantoin may stop germ cell maturation by preventing the uptake of the carbohydrates and oxygen that are required for the correct function of cells involved in spermatogenesis. The effects on sperm parameters, characterized by decreased sperm count and motility, are reversible after stopping the antibiotic treatment. However, in the context of testicular infections and epididymitis, antibiotic treatment is recommended as a result of its favourable impact on sperm quality (Schlegel et al., 1991; Hargreaves et al., 1998; Kilarkaje Narayana, 2008a; Khaki, 2008; Murdia et al., 1978; Nudell et al., 2002; Millsop et al., 2013; Schlosser et al., 2007; Haidl et al., 2008; Y aniz et al., 2010; Boitrelle et al., 2012; Hamada et al., 2011; VIDAL Hoptimal 2016) .
Ketoconazole is an antifungal drug that inhibits the action of the cytochromes P450 enzymes, involved in steroidogenesis. The blockade of the enzyme complexes 17a Hydroxylase and 17-20 Desmolase therefore results in the reduced synthesis of androgens and intratesticular testosterone. A reversible alteration in sperm parameters is possible. Men are advised to stop taking Ketoconazole before conceiving (Pont et al., 1982; Joshi et al., 1994; Millsop et al., 2013; VIDAL Hoptimal 2016) .
Chloroquine is an antimalarial drug, a lysosome stabilizer that acts as a protease inhibitor. It can theoretically inhibit the acrosome reaction of spermatozoa and reduce their fertilization capacity. However, the data in the literature that describe the impact of Chloroquine on male fertility are still insufficient (Okanlawon et al., 1993; Adeeko & Dada, 1994; Hargreaves et al., 1998; Østensen et al., 2006; Grunewald et al., 2007; Millsop et al., 2013) .
Ribavirin, which is used to treat chronic hepatitis C, reversibly alters germ cells. Sperm motility and morphology are reversibly altered and recover 4 months after stopping the drug (Pecou et al., 2009 ). This nucleoside synthesis analogue inhibits inosine monophosphate dehydrogenase, an enzyme that is involved in the biosynthesis of guanosine triphosphate in DNA and RNA, thus preventing cell growth. This results in increased apoptosis, defective multiplication and cellular differentiation in the germ cells of the seminal epithelium (Narayana et al., 2002; Durazzo et al., 2006; Pecou et al., 2009; Hofer et al., 2010; VIDAL Hoptimal 2016) .
Some studies suggest that antiretroviral drugs have a negative effect on sperm parameters, especially motility. To date, no final conclusion has been reached as to the actual gametic effects of these treatments because of the presence of confounding factors may be related to the HIV infection. Moreover, the possible toxicity of antiretroviral treatments for sperm parameters must be qualified as it is greatly outweighed by the medical benefits of the combined therapy. Nucleoside reverse transcriptase inhibitors (Zidovudine, Stavudine) could inhibit mitochondrial DNA replication (polymerase c) in the spermatozoa, whereas properly functioning mitochondria are vital to the energy supply that is required for their motility. Protease inhibitors are thought to prevent apoptosis that cause an alteration in sperm quality (Nicopoullos et al., 2004; Sergerie et al., 2004; Bujan et al., 2007; van Leeuwen et al., 2008; Kehl et al., 2011; Brezina et al., 2012; Frapsauce et al., 2015) .
Cimetidine
Cimetidine is an antihistamine that is used in the symptomatic treatment of gastro-oesophageal reflux disease. It has antiandrogen properties that result from a competition phenomenon at the level of the dihydrotestosterone receptors in the target cells; nevertheless, hyperprolactinemia is theoretically also possible (Fig. 3) . In animals, this molecule could also damage the peritubular myoid cells of the testis, leading to abnormal spermatogenesis. In men, the drop in spermatozoa production causing decreased sperm count is reversible 3 months after stopping the treatment (Van Thiel et al., 1979; Winters et al., 1979; Wang et al., 1982; Franc ßa et al., 2000; Nudell et al., 2002; Schlosser et al., 2007; Millsop et al., 2013) .
Antidepressants
Serotonin reuptake inhibitors (SRIs) are the standard treatment for depression. Tricyclic antidepressants act by inhibiting catecholamine recapture at a central level. Tricyclic antidepressants and serotonin reuptake inhibitors (SRIs) are responsible for hyperprolactinemia, which inhibits the hypothalamic-pituitary axis (Fig. 3) . In the case of hypogonadism, there may be adverse effects on sperm parameters (Nudell et al., 2002; De Rosa et al., 2003; Schlosser et al., 2007; Tanrikut & Schlegel, 2007) . SRIs could alter sperm count and motility. Adverse effects on sperm morphology are controversial. SRIs could also alter sperm quality via a mechanism that affects sperm transport. In particular, they increase DNA fragmentation in the spermatozoa, especially Paroxetine (Tanrikut & Schlegel, 2007; Safarinejad, 2008; Tanrikut et al., 2010; Brezina et al., 2012; Erdemir et al., 2014) .
The pharmacological substances that affect the central nervous system are also likely to modify erectile or ejaculatory functions. Antidepressants are often described as being responsible for sexual disorders, but in practice it is difficult to make a distinction between the effect of the drug treatment and the condition itself. Indeed, uncertainty arises regarding the central neuropharmacology of erectile function and the complex nature of the mode of action of antidepressants and psychiatric conditions (Baldwin & Mayers, 2003; Giuliano & Droupy, 2013) .
Serotonin reuptake inhibitors (SRIs) boost the neurotransmission of serotonin, a substance that inhibits male sexual behaviour. A loss of desire and anorgasmia are frequently reported during SRI treatment. Delayed ejaculation, or even anejaculation, also begins to occur a few weeks after the initiation of treatment. Paroxetine and Venlafaxine could also cause erectile dysfunction, by inhibiting NO production and increasing norepinephrine levels, respectively (Fig. 4) (Hendry, 1998; Montejo et al., 2001; Nudell et al., 2002; Baldwin & Mayers, 2003; Rosen & Marin, 2003; Droupy, 2005; Schlosser et al., 2007; Dording et al., 2008; Althof et al., 2010; Gratzke et al., 2010; Giuliano & Droupy, 2013; Taylor et al., 2013; Clayton et al., 2014; VIDAL Hoptimal 2016) .
During treatment by tricyclic antidepressants, anorgasmia, loss of desire, delayed ejaculation/anejaculation and erectile disorders are possible.
Monoamine oxidase inhibitors (MAOIs), which are less frequently prescribed, rarely cause erectile disorders because they are less associated with hyperprolactinemia (De Rosa et al., 2003) (Fig. 3) .
Bupropion, Mirtazapine and Buspirone do not cause sexual disorders (Hendry, 1998; Montejo et al., 2001; Nudell et al., 2002; Baldwin & Mayers, 2003; Rosen & Marin, 2003; Schlosser et al., 2007; Althof et al., 2010; Gratzke et al., 2010; Giuliano & Droupy, 2013; Taylor et al., 2013; Clayton et al., 2014; VIDAL Hoptimal 2016) .
Depression is a chronic condition, and in most cases the discontinuation of antidepressant treatment is not an option. In the event that sexual disorders arise during treatment with SRIs or tricyclic antidepressants, treatment with Bupropion, Mirtazapine, Buspirone or Moclobemide could be considered. However, it is always difficult to change the treatment of a depressive illness. There is insufficient data regarding the benefits of "treatment breaks" or a reduced dosage in terms of improving sexual function in depressive subjects (Droupy, 2005; Taylor et al., 2013; Clayton et al., 2014) .
Antipsychotics
Like tricyclic antidepressants and SRIs, "typical" neuroleptics are responsible for hyperprolactinemia by blocking central dopamine secretion, and indirectly cause hypogonadism (Fig. 3) . Adverse effects on spermatogenesis and sperm quality are theoretically possible by this pathway (Panidis et al., 1997; De Rosa et al., 2003; Schlosser et al., 2007) ; "typical" neuroleptics also affect the sexuality of patients who are receiving these treatments by inducing anorgasmia, decreased libido, ejaculation and erection disorders (Fig. 3) . In contrast, the "atypical" neuroleptics barely raise prolactin levels, if at all (De Rosa et al., 2003; Howes et al., 2007; Gratzke et al., 2010; Giuliano & Droupy, 2013) . The dysfunctions that are observed during treatment also result from an antipsychotic-induced anticholinergic effect and the blockage of b-adrenergic transmission (Fig. 4) . It is extremely difficult to distinguish between sexual disorders that can be attributed to a psychotic illness, and those that can be attributed to the use of a medication. Moreover, the information that has been gathered comes from psychiatric patients and is often difficult to interpret. As psychoses are chronic conditions, stopping the neuroleptic treatment is impossible in most cases. If sexual dysfunction arises while taking Haloperidol or Amisulpride (phenothiazines: "typical" neuroleptics), it may be possible to switch to a medication in a different therapeutic class, such as Quetiapine, Aripiprazole, Olanzapine or Clozapine ("atypical" neuroleptics). However, most of the time it is difficult to modify antipsychotic treatment (Hendry, 1998; Baldwin & Mayers, 2003; Howes et al., 2007; Schlosser et al., 2007; Gratzke et al., 2010; Serretti & Chiesa, 2011; Giuliano & Droupy, 2013) .
Antiepileptics
There are several hypotheses as to the possible impact of antiepileptics on the sperm parameters. Valproate, Carbamazepine and Phenytoin could reduce sperm motility by interfering with sperm membrane function, indeed Valproate reduces the L-carnitine/T-carnitine ratio. Similarly, Carbamazepine is thought to interact directly with germ cells, inducing a greater number of necrotic germ cells in the lumen of the seminiferous tubules. Valproate is responsible for reduced testicular weight in animals, which would indicate that the molecule has a harmful effect on spermatogenesis (Chen et al., 1992; Isoj€ arvi et al., 2004; Isoj€ arvi et al., 2005; de Oliva & Miraglia, 2009; Brezina et al., 2012) . Some anticonvulsants (Carbamazepine, Phenytoin and Phenobarbital) are hepatic enzyme inducers. They increase the synthesis of the SHBG protein, which is involved in testosterone transport, and they raise the total testosterone level. However, a lower level of bioactive serum androgens (testosterone) is sometimes observed when these molecules are used; bioavailable testosterone should always be measured in the framework of an antiepileptic treatment. Valproate does not increase SHBG, but it does raise the level of GABA in the central nervous system, thus modifying GnRH pulsatility. Valproate may also be responsible for increased serum androgen levels, and a possible reduction in LH owing to feedback. The impact of the new antiepileptics (Felbamate, Levetiracetam, Tiagabine, Topiramate, Vigabatrin, etc.) on hormone function has not been studied (Webber et al., 1986; R€ atty€ a et al., 2001; Isoj€ arvi et al., 2004 Isoj€ arvi et al., , 2005 Røste et al., 2005; Lossius et al., 2007; Herzog, 2008) .
Sexual dysfunction in epileptic patients has multifactorial causes. It results from the pathophysiology of the epileptic illness and the associated anticonvulsant treatments. It is generally impossible to distinguish between the sexual disorders that can be attributed to the epilepsy and those that can be attributed to the use of medication. Indeed, for ethical reasons, epileptic men are rarely antiepileptic treatment na€ ıve. During seizures, the epileptiform (temporolimbic) discharges disrupt neuroendocrine functions and modify hypothalamic and pituitary hormone release (resulting in elevated prolactin and fluctuating LH levels). Some antiepileptics may contribute to neuroendocrine disorders that could alter male reproductive functions (the 650 Andrology, 2017, 5, 640-663 Table 2 Impact of drugs on sexual function (Gratzke et al., 2010; Giuliano & Droupy, 2013; Droupy, 2005; Hendry, 1998; Colpi et al., 2004; Schlosser et al., 2007; Nudell et al., 2002) Captopril, Enalapril (Grimm et al., 1997; Ferrario & Levy, 2002; Manolis & Doumas, 2012 ) Sartans: Losartan, Valsartan (Becker et al., 2001; Ferrario & Levy, 2002; Shindel et al., 2008; Manolis & Doumas, 2012 ) Antihypertensive drugs with central action:
Methyl-dopa, Clonidine (Ferrario & Levy, 2002 ) Other: Reserpin (Ferrario & Levy, 2002) General reviews: (Giuliano et al., 2004; Karavitakis et al., 2011) (Bruckert et al., 1996; Rizvi et al., 2002; Saltzman et al., 2004; Solomon et al., 2006; Do et al., 2009 ; VIDAL Hoptimal 2016) Fibrates: Fenofibrate, Gemfibrozil, Clofibrate (Bain et al., 1990; Bruckert et al., 1996; Rizvi et al., 2002; VIDAL Hoptimal 2016) Herzog, 2008; Calabr o et al., 2011; Kaufman & Struck, 2011) .
Antihypertensives
Calcium channel blockers are thought to reduce the fertilization capacity of the sperm by decreasing sperm viability and motility and also by preventing spermatozoa-oocyte interaction as a result of the modified transmembrane movement of calcium, which has been described in vitro (Kanwar et al., 1993; Benoff et al., 1994; Schlosser et al., 2007; Brezina et al., 2012) .
Numerous data suggest that antihypertensives have a harmful effect on erectile function. However, it is difficult to determine the actual impact of these treatments as a result of the adverse effects of hypertension on erectile function, related to endothelial dysfunction (Giuliano et al., 2004) . There is still a great deal of controversy that surrounds the most commonly prescribed antihypertensives. The mechanisms through which these treatments affect sexual function are still largely unknown and may include a drop in blood pressure associated with a specific class effect (Grimm et al., 1997; Ferrario & Levy, 2002; Manolis & Doumas, 2012) .
Beta-blockers are thought to prevent corpora cavernosa vasodilatation by blocking the smooth muscle relaxation that is induced by the stimulation of b2 adrenergic receptors. Moreover, some of these molecules could reduce testosterone secretion as a result of an action at the central nervous system level. So-called "cardioselective" beta-blockers of the b1 adrenergic receptors have little (if any) effect on erectile function (Fig. 4) (Grimm et al., 1997; Ferrario & Levy, 2002; Nudell et al., 2002; Boydak et al., 2005; Droupy, 2005; Schlosser et al., 2007; Gratzke et al., 2010; VIDAL Hoptimal 2016) .
Centrally acting antihypertensives stimulate pre-synaptic a2-adrenergic receptors, thus reducing central sympathetic tone with possible repercussions for ejaculatory function (delayed reflex contractions of the bulbospongiosus muscles). Erectile dysfunction can also arise through the stimulation of the peripheral a-adrenergic receptors (Fig. 4) . Methyldopa is also responsible for hyperprolactinemia, which can inhibit the hypothalamic-pituitary-gonadal axis (Fig. 2) (Hendry, 1998; Ferrario & Levy, 2002; De Rosa et al., 2003; Droupy, 2005; Schlosser et al., 2007; Gratzke et al., 2010; VIDAL Hoptimal 2016) .
Alpha-blockers and calcium channel blockers do not cause erectile dysfunction, but ejaculatory disorders resulting from the use of these medications have been described, owing to the inhibition of bulbospongiosus muscle contractions.
Angiotensin-converting enzyme inhibitors and sartans do not alter erectile function. Indeed, angiotensin II is an important penile detumescence mediator. The literature review of Shindel et al. described the effects of drugs which improve endothelial function on the penile erection: Angiotensin II antagonists appeared to hold great promise in this regard (Shindel et al., 2008) . Moreover, Beker et al. showed that angiotensine II plasma levels are generally high in patients with an organogenic aetiology of erectile dysfunction; as a consequence, angiotensin inhibitors could be used in the treatment of vasculogenic erectile dysfunction (Becker et al., 2001) . Lastly, a recent literature review on implication of antihypertensive drugs on erectile dysfunction suggests that sartans are not associated with development of sexual dysfunction and that they may offer a therapeutic option to prevent or correct erectile dysfunction in patients with hypertension (Grimm et al., 1997; Becker et al., 2001; Ferrario & Levy, 2002; Nudell et al., 2002; Droupy, 2005; Schlosser et al., 2007; Gratzke et al., 2010; VIDAL Hoptimal 2016) .
In hypertensive subjects, the discontinuation of treatment is not recommended owing to the significant beneficial effect of antihypertensives in preventing cardiovascular events. However, it is important for practitioners to select the treatment carefully to limit the occurrence of sexual disorders. Angiotensin II antagonists thus appear to be the treatment of choice for sexually active men who are newly diagnosed with hypertension. When it is not possible to modify an antihypertensive treatment, an adjustment of the dose may be beneficial (Ferrario & Levy, 2002; Droupy, 2005; Karavitakis et al., 2011; Giuliano & Droupy, 2013) .
Hormonal treatments
GnRH analogues used in the treatment of prostate cancer temporarily raise gonadotrophin levels ("flare-up" effect). When 654 Andrology, 2017, 5, 640-663 administered daily, they subsequently inhibit gonadotrophin secretion via the desensitization of the pituitary receptors. The observed androgen blockage results in genuine chemical castration, which causes erectile dysfunction and a loss of libido (Basaria et al., 2002; Droupy, 2005; Giuliano & Droupy, 2013; VIDAL Hoptimal 2016) . A cross-sectional study of 58 men suggested that sexual dysfunction is noted in patients receiving androgen deprivation therapy for at least 12 months (Basaria et al., 2002) . More recently, a prospective study from 2008 to 2010 including 39 patients treated by androgen deprivation therapy showed that the administration of luteinizing hormone-releasing agonists induced significant decrease in penis length (Park et al., 2011) .
Intermittent androgen deprivation, when this is possible, reduces sexual function disorders and improves quality of life for men who suffer from prostate cancer (Iversen et al., 2001; Basaria et al., 2002) .
Tranquilizers
Benzodiazepines could induce erectile disorders via the inhibition of the proerectile central dopaminergic pathway (Ghadirian et al., 1992; Droupy, 2005; VIDAL Hoptimal 2016) .
A randomized double-blind, placebo-controlled multicenter study, including 604 patients, has shown that tramadol extended ejaculation latency time. This drug could become an effective treatment for premature ejaculation (use off-label) (Bar-Or et al., 2012) .
Anticholesterolemics
By activating PPARa, fibrates induce testosterone esterification, which results in erectile disorders.
Statins inhibit HMG-CoA reductase, an enzyme that is involved in cholesterol biosynthesis. As cholesterol is a precursor for steroid hormone synthesis, these molecules can theoretically affect erectile function in men who are being treated with medications that reduce androgen synthesis. However, only Simvastatin and Pravastatin are described as being potentially harmful; no disorders have been reported with Atorvastatin use. This is therefore not a class effect of statins (Bruckert et al., 1996; Rizvi et al., 2002; Saltzman et al., 2004; Solomon et al., 2006; Do et al., 2009; Gratzke et al., 2010) .
Digoxin
Digoxin could alter erectile function via the reduction in serum testosterone levels. It also has anticholinergic properties that prevent smooth muscle relaxation, an essential factor in the swelling of the corpora cavernosa (Neri et al., 1987; Gupta et al., 1998) .
DISCUSSION
In the framework of a male infertility workup, a history of drug treatments (present and past) taken by the patient must be obtained.
This systematic literature review has collated data related to all of the drugs with potential impacts on sperm parameters and/or sexual function. Some pharmaceutical treatments are described in the literature as being potentially harmful for male fertility, and yet it is not always easy for practitioners to access the available data. Furthermore, an evaluation of the actual gametic effects of these treatments remains to be performed.
Drug treatments and risks of infertility (excluding cytotoxic agents)
The (sometimes irreversible) gonadal damage caused by anticancer agents is now better understood and well documented Trottmann et al., 2007 . Conversely, data on the impact of drug treatments (excluding cytotoxic molecules) on male fertility are scarcer and sometimes controversial. Most of these data are nevertheless reassuring, with effects on spermatogenesis being reversible when described (Table 1) . A notable exception is the use of certain targeted therapies (Dabrafenib and Vismodegib) that are used to treat metastatic melanoma or basal-cell carcinoma. These medications exhibited a potentially irreversible impact on spermatogenesis in animals as a result of testicular degeneration, which was noted during pre-clinical safety studies. Given the potential risk of sterility in men, cryopreservation is indispensable prior to treatment. These molecules are teratogenic (but not mutagenic in vitro or in vivo in animals). The use of contraception during treatment is necessary with the cessation of drug in men who want to conceive (Grunewald & Jank, 2015; VIDAL Hoptimal 2016) . Although some molecules have reversible effect on sperm parameters, the cryopreservation can be proposed. This is the case, for Sulfasalazine, used for Crohn disease or ulcerative colitis (VIDAL Hoptimal 2016). It has been observed that spermatogenesis generally recovers approximately 2-5 months after stopping Sulfasalazine therapy (O'Mor ain et al., 1984; Østensen et al., 2006; Silva Clovis et al., 2010) . In patients with ulcerative colitis, the therapy with enteric-coated mezalasine (5-aminosalicylic acid preparation) allows the recovery of sperm alterations induced by Sulfasalazine (Kjaergaard et al., 1989; Silva Clovis et al., 2010) . Contraception and sperm banking are not necessary in patients treated with Sulfasalazine (Østensen et al., 2006) , but family planning must be discussed with all patients who need a treatment causing transient infertility (Silva Clovis et al., 2010) . Sperm banking can be proposed in men with a long-term treatment.
This is also the case with Cyproterone acetate used for palliative treatment of prostate cancer (VIDAL Hoptimal 2016). As the average age at the time of diagnosis is 66 years, sperm banking is generally not proposed before treatment. Nevertheless, in younger patients and/or in patients with a parental project, sperm banking should be discussed, especially as this treatment may also induce loss of erectile function and libido.
Finally, these therapy are often long-term treatment and stopping drug (or establish "drug holiday") is not often recommended.
Another important point is the frequency of bodybuilders taking testosterone supplementation therapy/anabolic steroids, being unaware of its negative impact on fertility, and presenting with azoospermia/severe oligozoospermia in infertility clinics (Wenker et al., 2015) . After withdrawal of exogenous testosterone, spermatogenesis is spontaneously reversible in an average of 3.2 months (Ly et al., 2005) and testicular sperm extraction should not be proposed.
Special case of mutagenic and/or teratogenic therapies
Even though they do not alter spermatogenesis, some immunosuppressants are likely to harm male fertility as a result of their mutagenic and teratogenic effects. This is the case with Azathioprine and Mycophenolate mofetil, for which cryopreservation must be proposed prior to the initiation of treatment, especially when subsequently stopping treatment cannot be envisaged (Dejaco et al., 2001; Ligumsky et al., 2005; Leroy et al., 2015 ; CRAT -Centre de r ef erence sur les agents t eratog enes chez la femme enceinte 2016). However, several recent studies have suggested no significant increase in the number of congenital anomalies in children born of fathers who were treated with Azathioprine or Mycophenolate mofetil (Hoeltzenbein et al., 2012; Jones et al., 2013) . In men who want to conceive, the discontinuation of treatment for a minimum of 3 months before conception is essential.
Sirolimus does not appear to definitively harm male fertility. This molecule is not mutagenic (in vitro or in vivo), but has been demonstrated to be embryotoxic and foetotoxic in animals. Owing to a potential clinical risk for descendants, conception while taking Sirolimus is not recommended (Leroy et al., 2015; VIDAL Hoptimal 2016) .
Methotrexate, a cytotoxic agent that is also indicated for numerous autoimmune conditions, is gonadotoxic, mutagenic and probably teratogenic, but its effects are reversed after the discontinuation of treatment. It is, therefore, important to reassure patients with regards to their future fertility. However, cryopreservation must be considered prior to the initiation of treatment if it cannot subsequently be stopped (Weber-Schoendorfer et al., 2014; Leroy et al., 2015 ; CRAT -Centre de r ef erence sur les agents t eratog enes chez la femme enceinte 2016; VIDAL Hoptimal 2016).
Treatment with a mutagenic drug must be discontinued for a minimum of 3 months before conception. (CRAT -Centre de r ef erence sur les agents t eratog enes chez la femme enceinte 2016). For only teratogenic molecules, studies recommend the discontinuation of treatment before the conception and the practice of safe sex when the partner is pregnant. In fact, the drug can be found in the seminal fluid and can possibly cross female mucus membranes (Millsop et al., 2013; Grunewald & Jank, 2015; Leroy et al., 2015) .
Variability in levels of evidence
Part of this summary work consisted of an examination of the level of evidence of the available studies and reviews, the results of which vary and depend on the molecules that are involved and their impact on male fertility.
Drugs and the impact on sperm parameters
For most of the drugs that are likely to affect spermatogenesis and/or sperm parameters, the levels of scientific evidence are still insufficient (with the exception of Sirolimus, Sulfasalazine, exogenous testosterone, Finasteride and Cyproterone acetate, for which the levels of evidence are higher) ( Table 1) . In some cases, data in men do not even exist, and the toxicity of a drug for the male reproductive organs is determined solely on the basis of animal models (rodents +++). When a pharmaceutical substance is developed with a view to obtain marketing authorization, pre-clinical safety studies that are performed in animals (rodents + other mammal species) are a means of predicting potential adverse effects on human fertility. The performance of future clinical trials (in men) therefore depends directly on the results of the data obtained in animals. However, care must be taken when extrapolating data from animals to humans. Indeed, the predictive power of pre-clinical animal toxicity studies for human reproductive functions, particularly male fertility (best evaluation of teratogenicity), is by no means infallible in terms of assessing the reprotoxicity of a pharmaceutical substance (Guittin et al., 1998) .
In humans, most studies are performed on small samples or even on case series (Tanrikut & Schlegel, 2007; Pecou et al., 2009) and do not always include a placebo group or a control group (Hofer et al., 2010) . Nor do a certain number of studies take into account the relationship between the dose of a drug and its impact, the effects of the residual illness on male fertility (impact of the illness itself) (Isoj€ arvi et al., 2004; Bujan et al., 2007) or the presence of other confounding factors that could be associated with the treatment (Schill et al., 2008) . Moreover, inter-/ intraindividual fluctuations in sperm parameters (caused by environmental factors, periods of abstinence, stress, smoking, etc.) and delayed repercussions of drug exposure on spermatogenesis (the complete spermatogenesis process takes 74 days) make it more difficult to analyse the results (studies with high statistical powers minimize this problem) (Levitas et al., 2005; Aitken, 2006) . Furthermore, in many cases the sole criterion that is considered in the evaluation of male fertility is the quality of the semen analysis. However, an alteration in sperm parameters does not always reflect the ability of the spermatozoa to fertilize the oocyte, or the likelihood of a pregnancy or a subsequent live birth.
Drugs and impact on sexual function
The impact of drug treatments on sexual function is most accurately assessed with higher levels of scientific evidence, as is the case with opiates, GnRH analogues, antiandrogens and alpha-blockers ( Table 2 ). The mechanisms of action through which GnRH analogues and antiandrogens are likely to cause erectile dysfunction are better defined and are closely related to the physiology of the erection. The blockage or reduction in androgens as a result of the administration of these treatments is thought to be the cause of the decreased peripheral expression of neuronal nitric oxide synthase, an enzyme that is involved in the synthesis of NO, which plays a vital role in the relaxation of the smooth muscle cells of the corpora cavernosa during tumescence (Schirar et al., 1997; Droupy, 2005; Courtois & Bonierbale, 2016) . As for alpha-blockers, these interfere with the physiological processes of ejaculation. Their sympatholytic effects result in defective seminal tract contraction and bladder neck closure, two mechanisms that depend on thoracic and lumbar sympathetic afference (Courtois & Bonierbale, 2016) .
For a certain number of pharmaceutical molecules that are likely to affect the sexual function of men being treated, the actual imputability of the drug is often difficult to pinpoint owing to the effect of the illness itself on sexuality (cardiovascular disease and erectile dysfunction; depressive illness and loss of desire, etc.) (Ferrario & Levy, 2002; Baldwin & Mayers, 2003) . When an erectile and/or ejaculatory disorder arises during treatment, it is important to retrace the patient's precise sexual history to establish any connection between the time when the treatment was started and the disorder first arose. If normal sexual function returns after the patient stops taking the drug, this would appear to indicate that the therapy was the true causal factor of the sexual dysfunction.
The low levels of evidence that were found are owing to the methodological difficulties inherent in the performance of reprotoxicity studies. Randomized controlled trials are scarce and require a sound methodological strategy at the outset. The meticulous monitoring of the selected patients along with highquality data collection throughout the study are vital. It is not easy to set up a placebo/control group, especially as the impact of the illness is a causal factor that is difficult to eliminate in practice (there are few treatment-na€ ıve patients, for ethical reasons). It is difficult to perform meta-analyses owing to the insufficient quantity of data available and the difficulties of harmonizing the studies that are selected for the population being studied (as a result of numerous associated confounding factors), the illness and the associated type of treatment (doses, duration of treatment, drug combinations, etc.).
CONCLUSION AND PERSPECTIVES
Medications are a frequent exogenous factor found in systematic evaluation of infertile men, but drugs' effects on the reproductive function (spermatogenesis, sperm parameters and sexual function) are often unclear, apart from few well-known reprotoxic pharmacological classes. Although the data should be updated regularly, this systematic review could be helpfully used in the framework of treating male infertility: it gives reproductive clinicians and biologists rapid access to pertinent information on a drug they suspect of being incriminated, and to clinical recommendations for patient fertility and sexual management.
